{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:15:34Z","timestamp":1777389334309,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s12072-015-9612-6","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T11:56:34Z","timestamp":1426074994000},"page":"224-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy"],"prefix":"10.1007","volume":"9","author":[{"given":"Edith Y.","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Jenny","family":"Heathcote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George K. K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"issue":"4","key":"9612_CR1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","volume":"45","author":"JH Hoofnagle","year":"2007","unstructured":"Hoofnagle JH, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45(4):1056\u20131075","journal-title":"Hepatology"},{"issue":"6","key":"9612_CR2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","volume":"37","author":"AL Cheng","year":"2003","unstructured":"Cheng AL, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6):1320\u20131328","journal-title":"Hepatology"},{"issue":"1","key":"9612_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok AS, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182\u2013188","journal-title":"Gastroenterology"},{"issue":"7","key":"9612_CR4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519\u2013528","journal-title":"Ann Intern Med"},{"issue":"3","key":"9612_CR5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299\u2013307","journal-title":"J Med Virol"},{"issue":"2","key":"9612_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","volume":"43","author":"W Yeo","year":"2006","unstructured":"Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43(2):209\u2013220","journal-title":"Hepatology"},{"issue":"4","key":"9612_CR7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605\u2013611","journal-title":"J Clin Oncol"},{"issue":"5","key":"9612_CR8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","volume":"136","author":"G Lalazar","year":"2007","unstructured":"Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136(5):699\u2013712","journal-title":"Br J Haematol"},{"issue":"270","key":"9612_CR9","first-page":"911","volume":"73","author":"JY Lau","year":"1989","unstructured":"Lau JY, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med. 1989;73(270):911\u2013917","journal-title":"Q J Med"},{"issue":"1","key":"9612_CR10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","volume":"68","author":"JR Wands","year":"1975","unstructured":"Wands JR, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68(1):105\u2013112","journal-title":"Gastroenterology"},{"issue":"3","key":"9612_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9071(200003)60:3<249::AID-JMV1>3.0.CO;2-C","volume":"60","author":"JL Steinberg","year":"2000","unstructured":"Steinberg JL, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore\/core mutations may play an important role. J Med Virol. 2000;60(3):249\u2013255","journal-title":"J Med Virol"},{"issue":"4","key":"9612_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","volume":"70","author":"W Yeo","year":"2003","unstructured":"Yeo W, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70(4):553\u2013561","journal-title":"J Med Virol"},{"issue":"8","key":"9612_CR13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431\u20131439","journal-title":"J Clin Oncol"},{"issue":"14","key":"9612_CR14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","volume":"332","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20\u00a0years of follow-up. N Engl J Med. 1995;332(14):901\u2013906","journal-title":"N Engl J Med"},{"issue":"4","key":"9612_CR15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.coc.0000159554.97885.88","volume":"28","author":"W Yeo","year":"2005","unstructured":"Yeo W, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005;28(4):379\u2013384","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"9612_CR16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1386-6346(03)00158-X","volume":"26","author":"H Nagamatsu","year":"2003","unstructured":"Nagamatsu H, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res. 2003;26(4):293\u2013301","journal-title":"Hepatol Res"},{"issue":"12","key":"9612_CR17","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1572-0241.2004.40069.x","volume":"99","author":"H Nagamatsu","year":"2004","unstructured":"Nagamatsu H, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004;99(12):2369\u20132375","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"9612_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","volume":"96","author":"JH Hoofnagle","year":"1982","unstructured":"Hoofnagle JH, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96(4):447\u2013449","journal-title":"Ann Intern Med"},{"issue":"2","key":"9612_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12072-008-9056-3","volume":"2","author":"GK Lau","year":"2008","unstructured":"Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152\u2013162","journal-title":"Hepatol Int"},{"issue":"1","key":"9612_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1040-8428(98)00042-0","volume":"31","author":"GK Lau","year":"1999","unstructured":"Lau GK, Lee CK, Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol. 1999;31(1):71\u201376","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"9612_CR21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.1999.17.1.394","volume":"17","author":"R Liang","year":"1999","unstructured":"Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17(1):394","journal-title":"J Clin Oncol"},{"issue":"5","key":"9612_CR22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.322","volume":"11","author":"L Xunrong","year":"2001","unstructured":"Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol. 2001;11(5):287\u2013299","journal-title":"Rev Med Virol"},{"issue":"4","key":"9612_CR23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","volume":"120","author":"RP Perrillo","year":"2001","unstructured":"Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009\u20131022","journal-title":"Gastroenterology"},{"issue":"5","key":"9612_CR24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.322","volume":"11","author":"L Xunrong","year":"2001","unstructured":"Xunrong L, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol. 2001;11(5):287\u2013299","journal-title":"Rev Med Virol"},{"issue":"5","key":"9612_CR25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","volume":"36","author":"TM Chan","year":"2002","unstructured":"Chan TM, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36(5):1246\u20131252","journal-title":"Hepatology"},{"issue":"3","key":"9612_CR26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","volume":"47","author":"C Hsu","year":"2008","unstructured":"Hsu C, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin\u2019s lymphoma: a randomized trial. Hepatology. 2008;47(3):844\u2013853","journal-title":"Hepatology"},{"issue":"4","key":"9612_CR27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.cld.2007.08.006","volume":"11","author":"HE Kohrt","year":"2007","unstructured":"Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11(4):965\u2013991","journal-title":"Clin Liver Dis"},{"issue":"7","key":"9612_CR28","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","volume":"99","author":"GK Lau","year":"2002","unstructured":"Lau GK, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324\u20132330","journal-title":"Blood"},{"issue":"6","key":"9612_CR29","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","volume":"125","author":"GKK Lau","year":"2003","unstructured":"Lau GKK, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742\u20131749","journal-title":"Gastroenterology"},{"issue":"1","key":"9612_CR30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","volume":"115","author":"G Rossi","year":"2001","unstructured":"Rossi G, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115(1):58\u201362","journal-title":"Br J Haematol"},{"issue":"17","key":"9612_CR31","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256\u20131263","journal-title":"N Engl J Med"},{"issue":"2","key":"9612_CR32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"CL Lai","year":"1998","unstructured":"Lai CL, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61\u201368","journal-title":"N Engl J Med"},{"issue":"4","key":"9612_CR33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","volume":"46","author":"SW Schalm","year":"2000","unstructured":"Schalm SW, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46(4):562\u2013568","journal-title":"Gut"},{"issue":"11","key":"9612_CR34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","volume":"19","author":"TT Chang","year":"2004","unstructured":"Chang TT, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19(11):1276\u20131282","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"9612_CR35","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714\u20131722","journal-title":"Gastroenterology"},{"issue":"1","key":"9612_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350601100113","volume":"11","author":"R Loomba","year":"2006","unstructured":"Loomba R, Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther. 2006;11(1):1\u201315","journal-title":"Antivir Ther"},{"issue":"2","key":"9612_CR37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2006-939757","volume":"26","author":"CK Hui","year":"2006","unstructured":"Hui CK, Lau GK. Current issues and future directions in treatment. Semin Liver Dis. 2006;26(2):192\u2013197","journal-title":"Semin Liver Dis"},{"issue":"3","key":"9612_CR38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM200501203520324","volume":"352","author":"F Perez-Roldan","year":"2005","unstructured":"Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005;352(3):310\u2013311","journal-title":"N Engl J Med"},{"issue":"9","key":"9612_CR39","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800\u2013807","journal-title":"N Engl J Med"},{"issue":"9","key":"9612_CR40","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"348","author":"P Marcellin","year":"2003","unstructured":"Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808\u2013816","journal-title":"N Engl J Med"},{"issue":"26","key":"9612_CR41","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","volume":"352","author":"SJ Hadziyannis","year":"2005","unstructured":"Hadziyannis SJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352(26):2673\u20132681","journal-title":"N Engl J Med"},{"issue":"6","key":"9612_CR42","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology. 2006;131(6):1743\u20131751","journal-title":"Gastroenterology"},{"issue":"4","key":"9612_CR43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/TCRM.S1965","volume":"4","author":"HL Tillmann","year":"2008","unstructured":"Tillmann HL. The treatment of chronic hepatitis B: focus on adefovir-like antivirals. Ther Clin Risk Manag. 2008;4(4):797\u2013802","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"9612_CR44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350501000507","volume":"10","author":"H Yang","year":"2005","unstructured":"Yang H, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10(5):625\u2013633","journal-title":"Antivir Ther"},{"issue":"8","key":"9612_CR45","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1572-0241.2004.40012.x","volume":"99","author":"M Enomoto","year":"2004","unstructured":"Enomoto M, et al. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin\u2019s lymphoma. Am J Gastroenterol. 2004;99(8):1619\u20131620","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"9612_CR46","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","volume":"54","author":"CK Hui","year":"2005","unstructured":"Hui CK, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54(11):1597\u20131603","journal-title":"Gut"},{"issue":"9","key":"9612_CR47","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cgh.2006.05.027","volume":"4","author":"AL Mindikoglu","year":"2006","unstructured":"Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006;4(9):1076\u20131081","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"9612_CR48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661\u2013662","journal-title":"Hepatology"},{"issue":"2","key":"9612_CR49","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507\u2013539","journal-title":"Hepatology"},{"key":"9612_CR50","doi-asserted-by":"crossref","unstructured":"Watanabe M, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21(4):333\u2013337","DOI":"10.1016\/j.ejim.2010.04.010"},{"key":"9612_CR51","doi-asserted-by":"crossref","unstructured":"Li HR, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18(12):877\u2013883","DOI":"10.1111\/j.1365-2893.2010.01386.x"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-015-9612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9612-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T23:16:40Z","timestamp":1651447000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-015-9612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["9612"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9612-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}